Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (22404)	6/17/1998 6:28:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

RB, If the letter was sent by regular mail instead of Fedex, anything is possible.

To: Russian Bear who wrote (22404)	6/17/1998 6:40:00 PM
From: celeryroot.com	Respond to of 32384

Three questions were submitted to the committee for a vote. The committee first voted 14 to 0 that the clinical results cited in the Biologic License Application for ONTAK are "reasonably likely to predict clinical benefit in patients with CTCL who have failed one or more systemic therapies." The committee further voted 14 to 0 that the toxicity associated with ONTAK treatment is "acceptable, given the response rates and durations of responses observed." By a vote of 12 to 2, the panel also recommended that treating physicians should decide the appropriate dose within a prescribed dose range.